Discover
ORKA
Oruka Therapeutics, Inc.
93.29
2 x 68.04
2 x 119.82
bid
ask
-
1.88
1.98%
2 @ 04:25 AM
91.99 -1.30 (1.39%)
| Ytd | 207.79% | |
| 1y | 690.59% |
92.92
day range
96.14
11.82
52 week range
97.78
| Open | 94.15 | Prev Close | 95.17 | Low | 92.92 | High | 96.14 | Mkt Cap | 5.63B |
| Vol | 1.38M | Avg Vol | 1.78M | EPS | -1.93 | P/E | N/A | Forward P/E | -37.43 |
| Beta | N/A | Short Ratio | 5.62 | Inst. Own | 89.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 68.39 | 200-d Avg | 41.61 | 1yr Est | 142.17 |
ORKA News
benzinga.com
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the pric
fool.com
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing
benzinga.com
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi
benzinga.com
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
benzinga.com
Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Parag
On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment